• Pharming Group (NASDAQ:PHAR) is now covered by analysts at Royal Bank of Canada. They set an outperform rating on the stock.The current price is $12.70.
Nabeurs toch een heel ander verhaal: 7.65 393 18:11:02.000 ? 7.4819 76,586 18:10:31.000 ? 7.4759 18,833 18:10:30.000 ? 7.78 1,134 18:10:01.000 ? 7.4913 245 18:09:02.000 ? 7.21 ...
Weet iemand of van de uitkering van € 14,5 dividendbelasting ( 25% ) ingehouden wordt ?
Abeona to host investor webinar on Tuesday, February 16, 2021 at 1:00 p.m. ESTNeurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO...
Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020
Number of shares issued at the end of the period 64,819,022Total current financial investments and cash and cash equivalents at the end of the period € 5,722,378.00064 mln aandelen met € 5.7 ...
ImegliminImeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles.Japan/Asi...
New coverage - healthcareSep. 12, 2019 8:54 AM ET|About: ANI Pharmaceuticals, Inc. (ANIP)|By: Douglas W. House, SA News EditUniQure NV (NASDAQ:QURE) initiated with Buy rating and $67 (41% upside) p...
Alle biofondsen staan onder druk. Bij de opening was de koers onveranderd en daarna gaat de koers langzaam volgens een vast patroon naar beneden. Kijk naar de daggrafiek. Overigens als er grote teg...
Positive Topline Phase 1 Results with THR-149 (Plasma Kallikrein Inhibitor) for treatment of DMEMixed Topline Results from exploratory THR-317 (anti-PlGF) Phase 2a ranibizumab combination study ...
Als de uitkomsten van 149 en 687 tegen waren gevallen hadden zij dat gelijk moeten melden dus ik verwacht beter nieuws dan de tegenvallende resultaten van 187.
Zien er toch schitterend uit ? Intrinsiek € 28, laat het bod maar komen !!
Initiation of Phase 2b NASH trial planned in 2H19. Pre-IND package submitted for VK2809; Initiation of Phase 2b NASH trial planned in 2H19. The company recently submitted a pre-investigational new ...
HALF-YEAR 2019 HIGHLIGHTS, RECENT DEVELOPMENTS AND OUTLOOK AsiDNA™ - In early January 2019, reporting of the identification of biomarkers predicting the response to AsiDNA™, which could optimize i...
June 11, 2019 GENFIT: Cymabay Phase 2 data: read-across for RESOLVE-IT? Dear investor, In reaction to the confusion generated by Cymabays Phase 2b announcement earlier today, wed like to bring to...
News Release Issued: Apr 11, 2019 (7:02am EDT)SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...
Press release Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting ...
Ts maar dat u het weet:Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00 at Cantor FitzgeraldPosted by ABMN Staff on Dec 17th, 2018 //
Beste HernaWij zijn op het niveau van 5!!!!!!!!!!!!!!!!!!! jaar geleden gekomen.Dat heeft alles te maken met aandeelhouderswaarde. Alleen vinden de echte aandeelhouders het een ander verhaal.
Toch niet de eerste de beste:TOP 10 KLANTEN (alfabetisch) ? ABN Amro ? Europese Commissie ? Havenbedrijf Rotterdam ? Johnson Johnson ? Ministerie van Binnenlandse Zaken ? Ministerie van Economisch...